Scarica l'app Stockscreener
4.00
3.09%
0.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
KalVista (NASDAQ: KALV) CMO’s stock, RSUs and options cancelled in $27-per-share Chiesi merger cleanup - Stock Titan
KalVista (NASDAQ: KALV) director’s options canceled and cashed out in $27 Chiesi deal - Stock Titan
KalVista (NASDAQ: KALV) COO’s RSUs and options cashed out in Chiesi merger - Stock Titan
Chiesi deal cancels options for KalVista (KALV) director Edward Unkart - Stock Titan
KalVista (NASDAQ: KALV) CEO equity cancelled for $27 cash deal - Stock Titan
KalVista Pharmaceuticals (KALV) CFO exits equity as Chiesi cash deal closes - Stock Titan
Vivo Opportunity entities (INM) add 249,227 InMed shares in open-market buys - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - TradingView
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
Layoff Tracker: Fulcrum axes 85% of staff after walking away from lead asset - BioSpace
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | MintzIntellectual Property Viewpoints - JD Supra
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - markets.businessinsider.com
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ADHD medication shortage reported by pharmaceutical companies - FOX Carolina News
XFOR: Advancing an oral therapy for chronic neutropenia with pivotal data in 2027 and FDA approval targeted for 2028 - TradingView
Justice Jackson Pens Unanimous Decision Backed by SCOTUS Conservatives - Newsweek
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - TradingView
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Alnylam (ALNY) director sells 3,830 shares after expiring option exercise - Stock Titan
Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options - Stock Titan
Mirum Pharmaceuticals (MIRM) CEO logs option exercise and 30K-share sale - Stock Titan
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
XFOR Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink initiates X4 Pharmaceuticals stock with outperform rating - Investing.com
Leerink Partners Initiates X4 Pharmaceuticals(XFOR.US) With Buy Rating, Announces Target Price $12 - Moomoo
Leerink Partners Initiates X4 Pharmaceuticals at Outperform With $12 Price Target - marketscreener.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FULL HOUSE RESORTS TO BREAK GROUND ON THE PERMANENT AMERICAN PLACE CASINO - Weekly Voice
New hires at rare-disease drugmaker get 160,000 stock options - Stock Titan
Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015 - Stock Titan
Fennec Pharmaceuticals (FENC) CEO receives 1,159-share stock award - Stock Titan
Trump Is Being Sued For Rescheduling Marijuana By Doctors And A Pharmaceutical Company Who Are 'Aggrieved' By The Move - Marijuana Moment
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals (XFOR) Gains 2.73% as Stock Tests Key Resistance LevelsRating Change - The Legal Advocate
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - TradingView
Recursion (NASDAQ: RXRX) director sells 40,000 shares in planned trade - Stock Titan
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
XFOR Q1 2026 Earnings: EPS Beats Estimates Despite Continued Pre-Revenue Status; Stock DeclinesQuarterly Earnings Report - thelegaladvocate.com
Torrent Pharmaceuticals Ltd. Hits All-Time High of Rs 4,698.8 as Momentum Builds Across Timeframes - Markets Mojo
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) CEO receives share grants under 2026 equity plan - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress - Yahoo Finance
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now - sharewise.com
Can Encompass Health's Expansion Strategy Make It a Hold for Now? - TradingView
X4 Pharmaceuticals (XFOR) Q1 2026 Earnings: Why the Beat MattersDebt Analysis Report - The Legal Advocate
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - GlobeNewswire
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):